This clinical trial is focused on studying the effects of the medication atorvastatin on the progression of prostate cancer in patients who are undergoing androgen deprivation therapy (ADT). Prostate cancer is a disease where cancer cells form in the tissues of the prostate, a gland in the male reproductive system. Androgen deprivation therapy is a treatment that reduces male hormones to slow the growth of cancer. The study aims to determine if atorvastatin can delay the progression of prostate cancer, specifically the development of resistance to castration, compared to a placebo during ADT for advanced prostate cancer.

Participants in the study will receive either atorvastatin, a cholesterol-lowering drug, or a placebo, which is an identical capsule without any active ingredient. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This approach helps ensure that the results are not influenced by expectations or bias. The trial will monitor the time it takes for the disease to progress after starting ADT or antiandrogen therapy.

The study will take place over a period of time, with regular check-ups to assess the health and progress of the participants. The goal is to gather information on whether atorvastatin can be an effective addition to the treatment of prostate cancer, potentially offering a new way to manage the disease and improve patient outcomes. Participants will be closely monitored throughout the study to ensure their safety and well-being.